# Formula W-1175: Advanced Metabolic Health Support

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. COMPOSITION & OVERVIEW

Formula W-1175 is a dual-agonist metabolic enhancement protocol designed for potent weight management and glycemic control. It combines a novel, orally active exercise mimetic with a next-generation oral GLP-1 receptor agonist.

| Component | Dosage | Primary Mechanism |
|---|---|---|
| **SLU-PP-332** | 10 mg | Pan-ERR (Estrogen-Related Receptor) Agonist; Exercise Mimetic |
| **Orforglipron** | 10 mg | Oral, Non-Peptide GLP-1 Receptor Agonist |

This combination targets two of the most powerful pathways in metabolic regulation—exercise-induced energy expenditure and incretin-based appetite suppression—to produce synergistic effects on body weight, fat mass, and glucose homeostasis.

---

## 2. DETAILED MECHANISM OF ACTION

Formula W-1175 employs a complementary two-pronged attack on metabolic dysregulation.

### 2.1 SLU-PP-332: Pharmacological Exercise Mimicry

SLU-PP-332 is a first-in-class, orally bioavailable pan-agonist of the Estrogen-Related Receptors (ERRα, ERRβ, ERRγ). The ERRs are nuclear receptors that function as master regulators of cellular energy metabolism, particularly in tissues with high energy demand like skeletal muscle, heart, and liver [1].

- **ERR Agonism:** By activating all three ERR isoforms, SLU-PP-332 induces a transcriptional program that mimics the effects of endurance exercise. This includes upregulating genes involved in:
    - **Fatty Acid Oxidation:** Increasing the muscle's capacity to burn fat for energy.
    - **Mitochondrial Biogenesis:** Promoting the creation of new mitochondria.
    - **Krebs Cycle (TCA) Activity:** Enhancing the central hub of cellular respiration.
- **Metabolic Shift:** In preclinical studies, SLU-PP-332 caused a significant shift in fuel preference from glucose to lipids, increased resting energy expenditure, and prevented diet-induced obesity without changes in food intake or physical activity [1]. It effectively puts the body's metabolic machinery into an "exercise mode" pharmacologically.

### 2.2 Orforglipron: Oral GLP-1 Receptor Agonism

Orforglipron is a novel, once-daily, oral, non-peptide agonist of the Glucagon-Like Peptide-1 (GLP-1) receptor. The GLP-1 system is a cornerstone of modern metabolic medicine.

- **Appetite Suppression:** Orforglipron activates GLP-1 receptors in the hypothalamus, leading to potent and sustained appetite suppression and reduced food cravings.
- **Glycemic Control:** It enhances glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying, all of which contribute to improved glycemic control.
- **Clinically Proven Weight Loss:** In a Phase 2 clinical trial published in *The New England Journal of Medicine*, orforglipron demonstrated a mean weight reduction of up to 14.7% at 36 weeks in adults with obesity [2]. Phase 3 trials have confirmed these robust weight loss effects [3].

### 2.3 Synergistic Architecture

The synergy between SLU-PP-332 and Orforglipron is powerful. Orforglipron reduces caloric intake by suppressing appetite (the "calories in" side of the equation). Simultaneously, SLU-PP-332 increases caloric expenditure by boosting resting energy expenditure and shifting the body's metabolism to preferentially burn fat (the "calories out" side). This dual-action approach—reducing energy intake while increasing energy expenditure—is a highly effective strategy for producing significant and sustained weight loss and metabolic improvement.

---

## 3. CLINICAL INDICATIONS & BENEFITS

Formula W-1175 is indicated for individuals with obesity, overweight with co-morbidities, pre-diabetes, and type 2 diabetes seeking significant weight loss and improved metabolic health.

| Category | Key Benefits |
|---|---|
| **Weight & Body Composition** | Clinically significant weight loss (approaching 15% or more); preferential reduction in fat mass; improved body composition. |
| **Metabolic Health** | Improved insulin sensitivity and glucose tolerance; reduction in HbA1c; lower plasma triglycerides and cholesterol. |
| **Appetite & Cravings** | Potent and sustained appetite suppression; reduced food cravings, particularly for high-fat and high-sugar foods. |
| **Energy & Fitness** | Increased resting energy expenditure; enhanced capacity for fatty acid oxidation, mimicking endurance training adaptations. |

---

## 4. DOSING, ADMINISTRATION & SAFETY

- **Standard Dose:** One capsule daily.
- **Administration:** Can be taken with or without food, without restrictions on water intake.
- **Safety Profile:** 
    - **Orforglipron:** The most common side effects are gastrointestinal in nature (nausea, vomiting, diarrhea), are typically mild to moderate, and tend to decrease over time. 
    - **SLU-PP-332:** As a novel compound, long-term human safety data is not yet available. Preclinical studies have shown a favorable safety profile.
- **Contraindications:** Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (class warning for GLP-1 RAs); pregnancy/lactation; known hypersensitivity.

---

## 5. REFERENCES

[1] Billon, C., et al. (2024). A pan-ERR agonist induces a thermogenic-like exercise-mimetic response in muscle. *Journal of Pharmacology and Experimental Therapeutics*, 388(2), 232-240. [https://doi.org/10.1124/jpet.123.001733](https://doi.org/10.1124/jpet.123.001733)

[2] Wharton, S., et al. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. *The New England Journal of Medicine*, 389(10), 877-888. [https://doi.org/10.1056/NEJMoa2302392](https://doi.org/10.1056/NEJMoa2302392)

[3] Lilly. (2023, June 23). *Lilly's phase 2 results published in The New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight* [Press release]. [https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-results-published-new-england-journal-medicine](https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-results-published-new-england-journal-medicine)
